Modelling critical parameters for drug discovery via intramuscular injection

Recent innovations in healthcare technology aim to improve the patient centricity of perenteral drug delivery. Clinical technologies that can deliver improved compliance while improving patient care and quality of life, include long acting injectables and pain free intradermal delivery devices.
With the growing number of long acting injection programs at GSK, the ability to model such formulations at an early stage will be an important step towards shortening development timelines, reducing costs, reducing animal usage, and gaining an overall better understanding of clinical performance. We have significant gap in our ability to assess the release rates of long acting injectable formulations prior to animal studies. An in vitro dissolution instrument specially designed to simulate physiological conditions of subcutaneous space for "immediate release" injectables has been developed by Professor Mrsny at University of Bath. The objective of this project will be to modify the instrument to better model critical aspects of ling acting injections administered both subcutaneously and intramuscularly.